Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor

Abstract

This invention features the use of the spirolaxine of formula (I) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the Type 2 insulin-resistant diabetes. This invention also features a pharmaceutical composition in which the spirolaxine of formula (I) acts as active principle in association with the all-trans retinoic acid of formula (II) for the treatment of those pathologies responding to the activation of the PPARγ receptor, such as the acute malignant haemopathies.

1 . Use of the spirolaxine of formula (I)  
       
         
           
           
               
               
           
         
       
       for the preparation of a medicament for the treatment of pathologies responding to the activation of the PPARγ receptor, with the proviso that the pathology is not tumor, hyperlipaemia or due to  helicobacter pylori.    
     
     
         2 . The use according to  claim 1 , wherein the pathology responding to the activation of the PPARγ receptor is the Type 2 insulin-resistant diabetes mellitus.  
     
     
         3 - 10 . (canceled)  
     
     
         11 . A method of treating a pathology excluding tumor, hyperlipaemia or due to  helicobacter pylori  responding to the activation of a PPARγ receptor comprising administering a spirolaxine of formula (I)